Literature DB >> 31849971

Commentary: p31-43 Gliadin Peptide Forms Oligomers and Induces NLRP3 Inflammasome/Caspase 1- Dependent Mucosal Damage in Small Intestine.

Exequiel Barrera1, Fernando Chirdo2, Sergio Pantano1.   

Abstract

Entities:  

Keywords:  celiac disease; coarse grained (CG); gliadin peptides; p31-43; simulations; sirah force field

Mesh:

Substances:

Year:  2019        PMID: 31849971      PMCID: PMC6895017          DOI: 10.3389/fimmu.2019.02792

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


× No keyword cloud information.
In our recent publication p31-43 Gliadin Peptide Forms Oligomers and Induces NLRP3 Inflammasome/Caspase 1- Dependent Mucosal Damage in Small Intestine” (1) we showed by a combination of experimental and simulation techniques that the peptide p31-43 Gliadin has an intrinsic propensity to form oligomers, which trigger the NLRP3 inflammasome, resulting in intestinal inflammation and pathology. In particular, molecular simulations performed with the SIRAH force field (2), showed that isolated p31-43 peptides exhibit a broad conformational dynamic with some PPII component, mostly related to the presence of Pro36 and Pro42. Simulation of multiple replicas showed a spontaneous tendency to aggregation with a concomitant increase in the PPII content for Pro38 and Pro 39. After our paper came out, an independent group published the NMR structure of p31-43 and its P36A and F37A mutants (3). This work presented apparently contrasting results based on NMR spectroscopy suggesting p31-43 Gliadin is mainly monomeric, but not discarding the presence of possible aggregated structures. As the peptide structures were deposited in the Protein Data Bank, we reanalyzed our molecular dynamics trajectory conducting a structural comparison between the conformations sampled in our simulations and those based on NMR. As it can be observed from Figure 1A, the matching observed between monomer simulations and experimental structures is outstanding. Moreover, the structural superposition between individual peptides within the aggregate and the experimental structures is also remarkable (Figure 1B). This provides support to the idea that “the monomers are in fast exchange with self-assembled structures” and that “the 3D models represent the secondary elements adopted also in the oligomeric forms” (3). Indeed, selected conformations from the simulations are indistinguishable from those coming from the experimental determination (Figure 1C).
Figure 1

Structural superposition of the best matching solution between NMR derived conformations and simulation of isolated peptides (A), and peptides within the 50-mer aggregate (B). On (C), the final structures obtained by molecular dynamics of each peptide forming the oligomer (Y-axis) are compared against all the conformers reported in the NMR family of structures (X-axis). The degree of structural similarity is reported as the root mean square deviation (RMSD) between the C-alpha carbons of simulated and NMR derived conformers. Small RMSD values (red-yellow) identify high structural similarity. Simulations of P36A and F37A showed the same degree of structural similarity (not shown).

Structural superposition of the best matching solution between NMR derived conformations and simulation of isolated peptides (A), and peptides within the 50-mer aggregate (B). On (C), the final structures obtained by molecular dynamics of each peptide forming the oligomer (Y-axis) are compared against all the conformers reported in the NMR family of structures (X-axis). The degree of structural similarity is reported as the root mean square deviation (RMSD) between the C-alpha carbons of simulated and NMR derived conformers. Small RMSD values (red-yellow) identify high structural similarity. Simulations of P36A and F37A showed the same degree of structural similarity (not shown). Besides highlighting the capacity of our simulation method to characterize the conformational behavior of peptides (Figure 1), the remarkable agreement between simulations and experiments in the oligomeric case provides strong support to the hypothesis that the p31-43 Gliadin peptide suffers very minor conformational changes when passing from monomeric to oligomeric states. This further strengthens the idea that aggregates might work as reservoirs that protect p31-43 from degradation. Though p31-43 monomers are quite resistant to degradation, the self-assembly process extends the persistence of large aggregates with higher toxic potency, particularly when disruption of the normal physiology of internal vesicles (1) and release of danger signals are considered as driving events for inflammation and cell damage (4).

Author Contributions

EB, FC, and SP wrote the paper.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
  4 in total

1.  The SIRAH 2.0 Force Field: Altius, Fortius, Citius.

Authors:  Matías R Machado; Exequiel E Barrera; Florencia Klein; Martín Sóñora; Steffano Silva; Sergio Pantano
Journal:  J Chem Theory Comput       Date:  2019-03-13       Impact factor: 6.006

2.  Structural insights on P31-43, a gliadin peptide able to promote an innate but not an adaptive response in celiac disease.

Authors:  Luisa Calvanese; Merlin Nanayakkara; Rosita Aitoro; Marina Sanseverino; Anna Lucia Tornesello; Lucia Falcigno; Gabriella D'Auria; Maria Vittoria Barone
Journal:  J Pept Sci       Date:  2019-03-25       Impact factor: 1.905

3.  p31-43 Gliadin Peptide Forms Oligomers and Induces NLRP3 Inflammasome/Caspase 1- Dependent Mucosal Damage in Small Intestine.

Authors:  María Florencia Gómez Castro; Emanuel Miculán; María Georgina Herrera; Carolina Ruera; Federico Perez; Eduardo Daniel Prieto; Exequiel Barrera; Sergio Pantano; Paula Carasi; Fernando Gabriel Chirdo
Journal:  Front Immunol       Date:  2019-01-30       Impact factor: 7.561

4.  Constitutive alterations in vesicular trafficking increase the sensitivity of cells from celiac disease patients to gliadin.

Authors:  Giuliana Lania; Merlin Nanayakkara; Mariantonia Maglio; Renata Auricchio; Monia Porpora; Mariangela Conte; Maria Antonietta De Matteis; Riccardo Rizzo; Alberto Luini; Valentina Discepolo; Riccardo Troncone; Salvatore Auricchio; Maria Vittoria Barone
Journal:  Commun Biol       Date:  2019-05-20
  4 in total
  2 in total

Review 1.  Interplay between Type 2 Transglutaminase (TG2), Gliadin Peptide 31-43 and Anti-TG2 Antibodies in Celiac Disease.

Authors:  Stefania Martucciello; Silvia Sposito; Carla Esposito; Gaetana Paolella; Ivana Caputo
Journal:  Int J Mol Sci       Date:  2020-05-23       Impact factor: 5.923

2.  Structural Perspective of Gliadin Peptides Active in Celiac Disease.

Authors:  Lucia Falcigno; Luisa Calvanese; Mariangela Conte; Merlin Nanayakkara; Maria Vittoria Barone; Gabriella D'Auria
Journal:  Int J Mol Sci       Date:  2020-12-06       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.